MoonLake Immunotherapeutics - Class A Ordinary Shares — Cash Flow (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities —-611.07 K-55.89 M-42.78 M-116.59 M-196.01 M -225.18 M Cash from investing activities —0-32.34 M-25.18 M-205.6 M202.99 M 58.91 M Cash from financing activities —-58.06 K119.69 M479.7 M51.31 M146 M 338.14 M Free cash flow —-611.07 K-55.89 M-42.78 M-116.59 M-196.01 M -225.18 M

News

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion (NASDAQ:MLTX)

MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-06-22

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23